Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Interventions
LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2), Bilateral sham procedure control (Part 2)
Drug
Lead sponsor
Lyra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Carlsbad, California • La Mesa, California • Roseville, California + 18 more
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Disseminated Neuroblastoma, Malignant Neoplasm, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Mixed Germ Cell Tumor, Ovarian Monodermal and Highly Specialized Teratoma, Ovarian Polyembryoma, Ovarian Yolk Sac Tumor, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Testicular Choriocarcinoma, Testicular Choriocarcinoma and Embryonal Carcinoma, Testicular Choriocarcinoma and Seminoma, Testicular Choriocarcinoma and Teratoma, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma, Testicular Embryonal Carcinoma and Seminoma, Testicular Embryonal Carcinoma and Teratoma, Testicular Embryonal Carcinoma and Teratoma With Seminoma, Testicular Embryonal Carcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor, Testicular Yolk Sac Tumor and Teratoma, Testicular Yolk Sac Tumor and Teratoma With Seminoma
Interventions
ipilimumab, therapeutic allogeneic lymphocytes
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts
Conditions
Sinusitis, Nasal Polyps
Interventions
Blood draw
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Dupixent Study for Alternate Administration

NCT06750471
Conditions
Nasal Polyps, Sinusitis, Chronic Disease
Interventions
Dupilumab
Biological
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Asthma, Respiratory Tract Disease, Lung Diseases, Sinusitis, Chronic
Interventions
Exposure-Reduction Intervention
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Sinusitis
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Joshua S. Jacobs
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Walnut Creek, California
Conditions
Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
Interventions
all macrolide antibiotics, all beta-lactam antibiotics
Drug
Lead sponsor
CPL Associates
Other
Eligibility
Up to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Spokane, Washington
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of PuraSinus Versus Bioresorbable Nasal Dressings

NCT04970966
Conditions
Chronic Sinus Disease, Surgery
Interventions
PuraSinus, Bioresorbable Nasal Dressing
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2 Interventional Results available

Esmolol vs. Labetalol in Endoscopic Sinus Surgery

NCT03661346
Conditions
Chronic Sinusitis
Interventions
Labetalol, Esmolol
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Lactobacillus sakei proBio65, Isotonic Saline Solution
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 1Phase 2 Interventional Results available

Topical Irrigation Therapy for CRS

NCT02630472
Conditions
Rhinitis, Sinusitis
Interventions
Quinine Sulfate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hidradenitis Suppurativa
Interventions
adalimumab, Placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more
Conditions
Chronic Sinusitis
Interventions
Merogel Nasal Stent and Nasopore Stent, Nasopore Stent and either Gentamycin or Bacitracin
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Burlington, Massachusetts
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Use of Perioperative Antibiotics in Endoscopic Sinus Surgery

NCT03369717
Conditions
Chronic Sinus Infection
Interventions
Amoxi Clavulanate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Cystic Fibrosis
Interventions
Elexacaftor-tezacaftor-ivacaftor exposure
Drug
Lead sponsor
Jennifer Taylor-Cousar
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Rhinosinusitis
Interventions
Laser + ICG, Laser only
Device
Lead sponsor
New York Head & Neck Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
New York, New York
Conditions
Sinusitis, Chronic Sinusitis
Interventions
Bacitracin, Nasopore sponge soaked with saline
Drug · Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Burlington, Massachusetts
Completed Phase 3 Interventional Results available

Dupilumab in CRSsNP

NCT04678856
Conditions
Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
Interventions
Dupilumab SAR231893, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Roseville, California • Stockton, California • Denver, Colorado + 7 more
Conditions
Chronic Sinusitis, Ethmoidal
Interventions
Steroid-eluting sinus implant, Post-op standard of care
Combination Product · Other
Lead sponsor
Collin County Ear Nose & Throat
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Frisco, Texas
Conditions
Chronic Rhinosinusitis
Interventions
oral corticosteroid taper
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Completed Not applicable Interventional Accepts healthy volunteers Results available

Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

NCT00626366
Conditions
Chronic Sinusitis
Interventions
Sinus CT Scan, Omnipaque 240 Contrast Solution, Omnipaque 240 mg I/mL
Radiation · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Sinusitis
Interventions
Amoxicillin-Potassium Clavulanate, Placebo
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts